Please assess the completion status of the following clinical trial:

Trial Title: The Impact of Pentoxifylline and Vitamin E on Radiotherapy-induced Toxicity in Head & Neck Cancer Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients~* Measurable disease~* Patients with squamous cell carcinoma of the head and neck eligible for treatment with concurrent chemo- radiotherapy~* Able to understand and willing to sign a written informed consent document~Exclusion Criteria:~* Pregnant or lactating women, since imaging cannot be done in this setting.~* Patients treated with vitamin E and/ or pentoxifylline for any other indication~* Patients with recent cerebral and/or retinal hemorrhage~* Patients who have previously exhibited intolerance to pentoxifylline or methylxanthines such as caffeine, theophylline, and theobromine.~* Patients treated with oral anticoagulants.~* Absolute neutrophil count ≤1.5×109/L~* Platelets ≤100×109/L~* AST ≥ 2.5 X institutional upper limit normal (ULN)~* Serum creatinine ≥ 1.5 mg% for males \& 1.4 mg% for females~* Serum bilirubin ≥ 1.5X institutional upper limit normal (ULN)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention Group (Type: EXPERIMENTAL): Platinum based concurrent chemoradiotherapy \[cisplatin (100mg/m2) on day 1, 22 and 43 of Radiotherapy (at 2 Gy/ fraction to a dose of 70 Gy over 7 weeks\] .~Pentoxifylline 400 mg oral tablets twice daily for 7 weeks. Vitamin E 1000 mg oral capsules once daily for 7 weeks.
- Control Group (Type: ACTIVE_COMPARATOR): Platinum based concurrent chemoradiotherapy \[cisplatin (100mg/m2) on day 1, 22 and 43 of Radiotherapy (at 2 Gy/ fraction to a dose of 70 Gy over 7 weeks\] .

Based on this trial design, predict the completion outcome and termination type (if applicable).